Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients

Belinostat is a hydroxamate class HDAC inhibitor that has demonstrated activity in peripheral T-cell lymphoma and is undergoing clinical trials for non-hematologic malignancies. We studied the pharmacokinetics of belinostat in hepatocellular carcinoma patients to determine the main pathway of metabo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ling-Zhi, Ramírez, Jacqueline, Yeo, Winnie, Chan, Mei-Yi Michelle, Thuya, Win-Lwin, Lau, Jie-Ying Amelia, Wan, Seow-Ching, Wong, Andrea Li-Ann, Zee, Ying-Kiat, Lim, Robert, Lee, Soo-Chin, Ho, Paul C., Lee, How-Sung, Chan, Anthony, Ansher, Sherry, Ratain, Mark J., Goh, Boon-Cher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559838/
https://www.ncbi.nlm.nih.gov/pubmed/23382909
http://dx.doi.org/10.1371/journal.pone.0054522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559838/
https://www.ncbi.nlm.nih.gov/pubmed/23382909
http://dx.doi.org/10.1371/journal.pone.0054522

Ejemplares similares